FDA hesitates on Arxxant

Share this article:
Regulators want an additional clinical trial for Eli Lilly’s diabetic retinopathy drug Arxxant (ruboxistaurin), the drug company said. The additional Phase 3 trial could take up to five years to complete,according to Lilly. The FDA requires the additional efficacy data before it will consider approval. An advisory committee had issued an approvable letter Aug. 18 requesting more data but delaying a decision on whether such data would come from ongoing trials or if a new trial would be required. Analysts had predicted Arxxant—which was in line to be the first approved oral treatment for the common eye disease—could have sales of at least $500 million a year. “We still believe that ruboxistaurin has potential as a treatment for diabetic eye disease and are exploring the feasibility of further development of this molecule,” said John Lechleiter, PhD, Lilly president and COO, in a statement. Trials will continue while Lilly evaluates its options. The firm submitted Arxxant to the FDA in February and received a priority, six-month review.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...